Pancreatic Cancer CRO
Support for pancreatic cancer trials as urgency stays high
Worldwide helps sponsors plan and run pancreatic ductal adenocarcinoma (PDAC) and other gastrointestinal cancer studies with support grounded in patient condition, enrollment realities, and protocol feasibility to help advance new treatment options for patients with high unmet need.
Tell us about your study
We’ll connect you with the right oncology clinical
development team.
Your PDAC Challenges
Built for the Realities of Pancreatic Cancer Trials
Pancreatic cancer trials are difficult to execute because patients can decline quickly, eligibility on paper does not always translate into meaningful study participation, and protocol demands can create too much burden for a very fragile population. For sponsors, that can affect screen fail rates, retention, enrollment quality, timelines, and study cost. Worldwide helps sponsors navigate that pressure with PDAC-specific experience, established site and investigator relationships, and support grounded in how these studies actually play out.
Patient Fragility Raises the Stakes Early
In pancreatic cancer, patients may qualify on paper but still be too ill to stay on study long enough to generate meaningful data. Worldwide helps sponsors plan with patient condition, burden, and protocol feasibility in mind.
Site Strategy Shapes Enrollment Quality
The right sites and investigators can directly affect enrollment, screen fails, and timelines. Worldwide brings established relationships with leading pancreatic cancer investigators and sites globally to support stronger study execution.
Protocol Burden Can Slow Participation
Long visits, complex assessments, and fragile patient condition can make participation harder for patients and caregivers. Worldwide helps sponsors pressure-test protocol demands so studies are more achievable in practice.
Experienced Judgement Helps Protect Momentum
PDAC studies require informed decisions from the start. With deep oncology leadership and experience across Phase I, II, and III pancreatic cancer studies, Worldwide helps sponsors plan and execute with greater confidence.
Partnership & Approach
Experienced Support from the Start
Worldwide brings experienced pancreatic cancer leadership into study planning at the start, helping sponsors think through the operational realities that can affect enrollment, retention, and data quality before those issues slow the study down.
Pancreatic Cancer Studies in the Past Five Years
Patients Enrolled
Unique Sites
Why Worldwide
What Makes Worldwide the Right Fit for Pancreatic Cancer Studies?
Worldwide brings pancreatic cancer experience, established investigator relationships, and patient-centered operational judgment that help sponsors plan more realistically, reduce avoidable risk, and move complex PDAC studies forward with greater confidence.
Extensive and Recent PDAC Experience
Worldwide brings pancreatic cancer experience across numerous metastatic PDAC studies, helping sponsors plan with a partner that understands the current demands of this indication, the competitive landscape, and where studies are most likely to get off track.
PDAC-Informed Site and Investigator Strategy
In pancreatic cancer, the right sites and investigators can significantly affect enrollment quality and study timelines. Worldwide brings established relationships with leading pancreatic cancer investigators and sites globally, helping sponsors identify investigators with meaningful experience and access to the right patients to support enrollment.
Treatment Pathway Expertise
Worldwide brings practical understanding of the pancreatic cancer treatment pathway, patient condition, and study burden considerations that can shape protocol design, participation, and speed to enrollment. That insight helps sponsors make more patient-centered decisions early.
Global PDAC Experience
Worldwide’s pancreatic cancer expertise includes experience across global PDAC trials and study phases, giving sponsors access to insight that supports feasibility, regional planning, and execution in a complex setting.
Countries of
PDAC Experience
Services & Capabilities
Comprehensive Oncology CRO Services
- Protocol Design and Clinical Development Planning
- Regulatory Consulting and Global Submissions
- Global Project Management
- Feasibility Analysis and Site Selection Strategy
- Site Initiation and Study Start-up
- Patient Enrollment
- Dose Escalation, Optimization and Cohort Management
- Site Monitoring and Management
- Data Management
- Clinical Data Analytics and Review
- Clinical Science
- Biostatistics
- Medical Monitoring
- Safety / Pharmacovigilance
- Medical Writing
Site and Investigator Strategy
Worldwide helps sponsors identify sites with meaningful pancreatic cancer experience and investigators who are active in this indication, with access to the right patients for the study.
Patient-Centered Operational Design
Our teams help sponsors review protocol demands through the lens of a very fragile patient population, including visit burden, caregiver impact, pain status, and the practical demands of study participation.
Survival Follow-Up Planning
Worldwide helps sponsors plan for the realities of enrolling large patient populations in a competitive trial landscape, with attention to site access, the patient journey, and local standards of care.
Feasibility and Study Planning for PDAC
We help sponsors evaluate whether eligibility criteria fit the actual patient population and whether the study design is realistic for sites and patients in this indication.
What Our Clients Say
“We really appreciate the strong collaborative partnership we’ve developed with Worldwide which is based on shared accountability. I see us awarding them more studies in the future.”
Sr. Vice President of Clinical Development and CMS – Late Phase | Clinical Stage Biotech Company
FAQ & Insights
What Sponsors Need to Know
Pancreatic cancer trials are especially challenging because the patient population is very ill, the treatment window can be short, and small operational issues can have an outsized effect on enrollment, retention, and data quality. In PDAC, success depends not only on finding eligible patients, but on identifying patients who are well enough to stay on study, tolerate treatment, and generate meaningful data.
Worldwide helps sponsors identify sites and investigators with meaningful pancreatic cancer experience, access to the right patients, and active engagement in this indication. In PDAC, those decisions can directly affect enrollment quality, timelines, and overall study performance.
Worldwide helps sponsors look beyond whether a patient is technically eligible on paper and focus on whether that patient is likely to remain on study long enough to contribute usable efficacy and safety data. In PDAC, that matters because stronger eligibility judgment can help improve enrollment quality, reduce screen fails and dropout, and avoid unnecessary cost tied to replacing patients or managing preventable disruption.
Worldwide approaches follow-up and overall survival data collection in PDAC with the understanding that this can be one of the most difficult parts of the study. Because patients may decline quickly or transition to hospice, follow-up plans need to be realistic, proactive, and built into the study strategy early to help protect data quality.
Worldwide brings significant Phase I-III pancreatic cancer experience across metastatic PDAC studies in the past five years, spanning 15 countries across North America, Europe and the Asia-Pacific regions. That experience supports more informed planning around feasibility, site strategy, patient realities, and the operational decisions that can shape study performance across regions.
Insights
Explore Our Pancreatic Oncology Insights
Oncology Expertise
Looking for Other Oncology Specializations?
See what Worldwide Clinical Trials can do for you.
Your study has unique goals, risks, and decisions ahead. Tell us a little about your needs, and our team will connect you with the right Worldwide experts to discuss how our scientific, medical, and operational support can help move your program forward with confidence.
